Rob Lin, PhD, CFA, is CEO of Avista Therapeutics. He was Founding CEO of BlueSphere Bio and currently serves on the board of directors of BlueSphere Bio, Code Biotherapeutics, and VegaVect, Inc. Previously, he was Vice President of Translational Science at UPMC Enterprises. He has also been CFO of Phlebotics and Vice President of Finance at the International Diseases Research Institute. Prior to that he led the finance and strategy team for the Global Health Program at the Gates Foundation and held strategy positions at Millennium Pharmaceuticals (now Takeda Oncology) and Dean and Company. He is a CFA Charterholder and Term Member of the Council on Foreign Relations. Rob holds a PhD in human genetics from Harvard University, an MMSc in medical sciences from Harvard Medical School, where he was a Harvard-Markey Biomedical Scientist Fellow, and an MS in Chemical Engineering from Stanford University.

Bruce Booth is a partner at Atlas Venture, where he focuses on the discovery and development of novel medicines and therapeutic platforms. He is also is chairman and was founding CEO of Kymera Therapeutics and Nimbus Therapeutics. He serves as chairman of Hotspot Therapeutics and Matchpoint Therapeutics and board member of Lifordi Immunotherapeutics and Sionna Therapeutics, as well as several seed-stage companies. He previously served on the boards of prior Atlas companies that have since been acquired. Bruce serves or has served as an advisor in various capacities to Takeda, UCB, the Gates Foundation, and the Penn State Research Foundation. He recently joined the board of the Appalachian Mountain Club and volunteers as a coach with New England Disabled Sports. Bruce blogs about biotech and venture capital topics at LifeSciVC.com. Prior to joining Atlas in 2005, he was a consultant at McKinsey & Company and an investor for Caxton Health Holdings. As a British Marshall Scholar, he holds a DPhil (PhD) in molecular immunology from Oxford University.

Ying Huang is a visionary oncology leader who has guided Legend Biotech to
the forefront of the global cell therapy revolution. Under his leadership, Legend has
helped transform outcomes for patients with multiple myeloma through the development
and commercialization of CARVYKTI® (ciltacabtagene autoleucel), a onetime CART cell
therapy developed in partnership with Johnson & Johnson. Since its launch, CARVYKTI® has been used to treat more than 10,000 patients worldwide and has delivered durable, unprecedented clinical benefit. Results from the landmark CARTITUDE1 study demonstrate that approximately one third of patients with relapsed or refractory multiple myeloma remain progression-free for five years or more following a single infusion, an achievement that has redefined expectations for long- term disease control and the future of cell therapy. Dr. Huang originally joined Legend in July 2019 as Chief Financial Officer. Prior to joining Legend Biotech, he served as Managing Director and Head of Biotech Equity Research at Bank of America Merrill Lynch and as a Principal Scientist at ScheringPlough. Since becoming CEO in 2020, he has fostered a deeply patient-centric, collaborative culture focused on advancing transformative therapies and expanding global access to innovative medicines.

Dr. Monia is the CEO, a member of the board of directors, and a founding scientist of Ionis Pharmaceuticals. His contributions at Ionis include research into the medicinal chemistry and mechanisms of action of RNA-targeting modalities to treat human diseases, most notably antisense-based therapeutic strategies. Dr. Monia has extensive experience across a range of therapeutic areas, including oncology, metabolic disease, inflammation, neurological disease and cardiovascular disease, which have resulted in a broad range of successful clinical achievements and in marketing approvals for new medicines. He has published more than 200 primary research manuscripts, reviews and book chapters, and is an inventor on more than 100 issued patents. He serves as a senior editor for the journal Nucleic Acid Therapeutics, sits on the board of directors of Cognition Therapeutics, and has also been president of the Oligonucleotide Therapeutics Society (OTS). Dr. Monia received his Ph.D. in Pharmacology at the University of Pennsylvania and B.S. degrees in Molecular Biology and Analytical Chemistry at Stockton State University in Pomona, New Jersey.

Esther Rajavelu is President and CEO of Spero Therapeutics, where she continues to serve as Chief Financial Officer and Chief Business Officer. She joined Spero in those finance roles in November 2023 and took over as chief executive in 2025. Ms. Rajavelu came to operating leadership from the investor side. She spent nearly two decades on Wall Street covering biotechnology and specialty pharmaceuticals as an equities research analyst at Deutsche Bank, Oppenheimer, and UBS, and earlier worked as a healthcare investment banker. She moved into industry in 2022 as Chief Financial Officer of Fulcrum Therapeutics, where she led equity financings and reset internal investment priorities to extend the company's cash runway. She holds an MBA in healthcare and finance from the Wharton School and a bachelor's degree in economics and government from Wesleyan University.

Dr. Helen Torley joined Halozyme in January 2014 as President and CEO. Under her leadership, the company has advanced its ENHANZE® technology into multiple blockbuster franchises for its partners, and established Halozyme as a leader in innovative drug delivery solutions with the recent acquisitions of Elektrofi’s Hypercon technology and Surf Bio. She brings almost three decades of biopharmaceutical leadership and a strong track record of building commercial organizations and launching high-impact medicines, having overseen several successful product launches, including Kyprolis®, Prolia®, Sensipar®, and Miacalcin®. Before joining Halozyme, Dr. Torley was Executive Vice President and Chief Commercial Officer of Onyx Pharmaceuticals from 2011 to 2013, where she led the U.S. launch of Kyprolis®, built Onyx’s exU.S. commercial capabilities—particularly in Europe—and managed the company’s commercial collaborations with Bayer on Nexavar® and Stivarga®. Prior to Onyx, Dr. Torley spent 10 years at Amgen, holding multiple senior leadership roles. She served as Vice President and General Manager of the U.S. Bone Health Business Unit (2009–2011) and the U.S. Nephrology Business Unit (2003–2009), helping drive major product growth and operational excellence across both portfolios. Earlier in her career, she held senior management roles at BristolMyers Squibb from 1997 to 2002, including Regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global Marketing. Dr. Torley began her professional career in clinical medicine as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland. She earned her Bachelor of Medicine and Bachelor of Surgery from the University of Glasgow and is a Member of the Royal College of Physicians.

Mikael Dolsten, MD, PhD, is a Board member of Agilent Technologies, Rocket Pharmaceuticals, Chai Discovery, BenchSci, and Enveda Biosciences. He is Chairman of Quarry Thera (founding CEO), Orbis Medicine, Orogen Therapeutics, and Mast Cell Sciences.

He is also Advisor to Blackstone, Google Ventures, and Canaan Partners, as well as Chair of the Prix Galien Bridges Committee and Member of the Prix Galien USA Committee.

He serves in governor or advisor roles for Orbis Medicine, Fair Journey Biologics, lmmuneAI, Arbor Biotechnologies, Orogen Therapeutics, Blackstone Life Sciences, Bain & Co, and Formation Bio. His supervisory affiliations include the Scripps Research lnstitute, the Foundation for the NIH, Research America, and membership in The Royal Swedish Academy of Engineering Sciences.

He recently retired from Pfizer lnc. after a 16-year tenure as Chief Scientific Officer and President of Pfizer Research & Development, where he oversaw the regulatory approval of over 36 medicines and vaccines, while advancing more than 150 drug candidates into clinical studies.

He has also been President of Wyeth Research, Executive Vice President and Head of Worldwide Research at Boehringer lngelheim, and Global VP at AstraZeneca. Earlier, he led R&D at Astra Draco and headed lmmunology Oncology research at Pharmacia, Sweden. Dr. Dolsten has VC experience from work with Orbimed, ATP, and Pfizer venture groups and has been involved in numerous small and large corporate business transactions exceeding  $1008 in size.

He has advised numerous U.S. government administrations  חסpublic health, and the UK Government's G7 leadership for pandemic responses.

With over 160 scientific publications and numerous patents, Dr. Dolsten holds both a Ph.D. in Tumor lmmunology and an M.D. from the University of Lund, Sweden, where he serves as a Visiting Professor. 

Dr. Cedric Francois, MD, PhD is the visionary Co-Founder and CEO of Apellis Pharmaceuticals (NASDAQ: APLS), which he and his cofounders built from the ground up from novel scientific concept to a life-changing pipeline, and successfully navigated through development, rapid team growth, public listing, and recently, commercialization.

Prior to co-founding our company, Cedric co-founded Potentia Pharmaceuticals, a private biotechnology company, which transacted with Alcon Research Ltd in 2009.

Cedric received his MD degree from the University of Leuven in Belgium and his PhD degree in physiology from the University of Louisville. Following postgraduate training in pediatric and transplant surgery, Cedric joined the research team that performed the first successful hand transplantation in Louisville in 1999.

Nick Leschly is a biotechnology executive and entrepreneur with over two decades of leadership experience advancing transformative therapies for patients. He is Founder and CEO of Atida Bio and Chair and Co-Founder of Altido Therapeutics. Previously, he was CEO of bluebird bio where he led the company for 12+ years, scaling it from an early-stage gene therapy startup to a publicly traded leader in cell and gene therapies. He subsequently guided the spin-out of 2seventy bio, an oncology-focused cell therapy company later acquired by Bristol Myers Squibb. Earlier in his career, he was a founding partner at Third Rock Ventures and held drug development roles at Millennium Pharmaceuticals. He holds a B.S. in molecular biology from Princeton and an MBA from the University of Pennsylvania’s Wharton School. He is a board member of Rethink Foods in NYC and The CEPIA School in Costa Rica.

Alex founded the Mark Cuban Cost Plus Drug Company after being incensed by the skyrocketing costs of generic drugs for his patients. He graduated from the University of Colorado at Boulder at the age of 18 with a BA in Biochemistry, then went on to earn an MD at the Duke University School of Medicine and a PhD (DPhil Oxon) at Oxford University in Mathematics as a Marshall Scholar. Alex completed a surgical internship at the Brigham and Women’s Hospital / Harvard Medical School and held a residency in diagnostic radiology, as well as a fellowship in pediatric radiology at the Johns Hopkins Hospital. He then served as an adjunct faculty member at the Stanford University School of Medicine and continues to practice as an emergency radiologist. While in graduate school, Alex founded Altitude Medical, a startup dedicated to reducing the rates of nosocomial diseases in hospitals.

John F. Crowley is the President and CEO of the Biotechnology Innovation Organization (BIO), the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe. He was previously the Founder and Executive Chairman of Amicus Therapeutics, where he also served as CEO from 2005 to 2022. John’s decades of biotech experience and deep passion for the field have made him a strong supporter of policies that empower innovation, enable entrepreneurship, and put people and patients first. His involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease, a severe and often fatal neuromuscular disorder. The 2010 major motion picture, Extraordinary Measures, is inspired by the Crowley family journey. He also served as a commissioned officer in the U.S. Navy Reserve from 2005-2016, including service to multiple arms of U.S. Government. He attended the U.S. Naval Academy and went on to earn a B.S. in Foreign Service from Georgetown University, a JD from the University of Notre Dame Law School, and an MBA from the Harvard Business School.

After earning her Ph.D. in Biochemistry from the University of Cincinnati, Dr. Du joined Pfizer in the United States in the early 1990s. At Pfizer central research, she played a key role in the development of multiple early and late-stage products, two of which received U.S. FDA approval. She also led the scientific efforts of Pfizer’s global metabolic licensing group. Dr. Du co-founded Hutchison MediPharma (HMP) and Hutchison China MediTech (Chi-Med, now HUTCHMED), serving as CEO and Chief Scientific Officer, respectively. After more than a decade in these roles, she then joined Sequoia Capital China and led several landmark healthcare investment deals and served on multiple public and private boards. Dr. Du founded Zai Lab in 2014 and took the company public on the NASDAQ in 2017. She is a recipient of numerous global awards and honors.

Mr. Paulsen joined the Ferring Board of Directors in July 2021, became Chairman of the Board in July 2023, and was appointed Chief Executive Officer on 1st February 2026. Since 2020, he has also served as Chairman of Ferring Ventures SA. He is a member of the Harvard Medical School Board of Fellows and Chairman of the Audit and Finance Committee of the State Pension Fund of Georgia. Additionally, he is Chairman of the International School of Economics at Tbilisi State University, having previously served as Senior Advisor to the Vice Prime Minister of Georgia. Before joining Ferring, Mr. Paulsen worked at Mars Inc., Coca-Cola and Credit Suisse. He holds a Master’s degree in Finance from the London School of Economics and Political Science and is a Fellow of the Chartered Institute of Management Accountants in the UK. 

Andrew Plump is President of R&D at Takeda and serves as a member of the company’s
board of directors. His career spans nearly 30 years in the pharmaceutical industry and academia. He has been recognized for his contributions to the healthcare industry, education and the arts. He serves on several not-for-profit boards, including the Board of Trustees for the Boston Symphony Orchestra, the Sarnoff Cardiovascular Research Foundation, the Biomedical Science Careers Program and as Chairman of the Board of Directors for the PhRMA Foundation. Prior to Takeda, Dr. Plump served as head of Research & Translational Medicine, Deputy to the president of R&D at Sanofi, based in Paris, France. Before that, he was Worldwide Cardiovascular Research Head at Merck. Dr. Plump received his M.D. from the University of California, San Francisco (UCSF), his Ph.D. in cardiovascular genetics and his B.S. from the Massachusetts Institute of Technology (MIT). He completed a residency in internal medicine and a fellowship in medical genetics at UCSF.

Joel S. Marcus, JD, CPA, is Executive Chairman and Founder of Alexandria Real Estate Equities, Inc. (NYSE: ARE), a real estate investment trust (REIT) that pioneered life science real estate and transformed it from a specialty niche to a mainstream asset class. Alexandria is the preeminent, largest, and longest-tenured owner, operator, and developer uniquely focused on collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations. Since co-founding Alexandria in 1994 as a garage startup with $19 million in Series A capital, he has led its remarkable growth into an S&P 500 company that has become the leading REIT focused on the life science industry, with a total market capitalization of $25.7 billion and an operating asset base of approximately 40 million square feet as of June 30, 2025.

Mr. Marcus also leads Alexandria Venture Investments, the company’s strategic venture capital platform, which he founded in 1996. Some of his most notable early-stage investments include Alnylam Pharmaceuticals, Google, and Intra-Cellular Therapies. With approximately $1.5 billion under management, Alexandria Venture Investments actively invests in disruptive life science companies that are advancing transformative new modalities, platforms, and innovative medicines to meaningfully improve human health.

Mr. Marcus introduced Alexandria’s thought leadership vertical in 2011 when he co-founded the renowned Alexandria Summit®, a highly collaborative, neutral platform that explores important issues facing human health and leverages its powerful collective voice to foster impactful collaborations and shape policy. He also leads Alexandria’s corporate responsibility initiatives, which aim to address some of the nation’s most urgent challenges, including the mental health crisis.

Mr. Marcus serves on the boards of several biotechnology companies and non-profits, including the Emily Krzyzewski Center, National Medal of Honor Museum, Navy SEAL Foundation, Office of Strategic Services Society, and TOPGUN Association. He served on the board of directors of Intra-Cellular Therapies from 2006 until its acquisition by Johnson & Johnson in 2025. Mr. Marcus received his undergraduate and Juris Doctor degrees from the University of California, Los Angeles.

Lynne Zydowsky, PhD, Chief of Science of Alexandria Real Estate Equities, Inc./Alexandria Venture Investments, President and Co-Founder of the Alexandria Summit, and President of Zydowsky Consultants, is an experienced executive in the life science industry who has been involved in the launching and building of several successful companies. With over 25 years of experience, Dr. Zydowsky has played key roles in corporate development, operations, and finance. She is a long-standing advocate for biomedical research and the advancement of global health.

In 2003, Dr. Zydowsky founded Zydowsky Consultants, a consulting practice offering services to life science companies. Prior to that, Dr. Zydowsky was Co-Founder and Chief Operating Officer of Renovis, Inc. (now Evotec) and served as Vice President of Pharmaceutical Business Development at Exelixis, Inc. As part of their executive management teams, she contributed to the growth and development of both companies, which led to their initial public offerings.

In 2011, Dr. Zydowsky, along with Mr. Joel Marcus and Ms. Deeda Blair, co-founded the Alexandria Summit. The neutral, interactive platform convenes a diverse group of visionary stakeholders for transformative discussions and collaborations that help drive the discovery and development of novel, cost-effective therapies; shape policy to advance innovation that saves lives and cures disease; and inspire new ways of addressing the urgent need to transform our healthcare system.

Dr. Zydowsky currently serves on the Board of Directors for the Reagan-Udall Foundation for the FDA (since October 2018); the Board of Trustees for Butler University (since September 2016); and the board of two private animal health companies.

Dr. Zydowsky is personally engaged in critical philanthropic efforts as a member of the Global Board for the international non-profit buildOn, an organization focused on breaking the cycle of poverty, illiteracy, and low expectations through its after-school programs for urban teens based on changing lives and communities through service locally and globally.

Dr. Zydowsky earned her PhD in Chemistry from The Ohio State University and was a National Institutes of Health postdoctoral fellow in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. She has a Bachelor of Science degree in Pharmacy from Butler University.

Dan Skovronsky is the chief scientific officer of Eli Lilly and Company and serves as Lilly’s executive vice president of science and technology. Dan is also president of Lilly Research Laboratories and president of Lilly Immunology, as well as has responsibility for global business development.

Dan joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals Inc., where he had been CEO since founding the company in 2004. At Lilly, he has held various leadership roles, including chief medical officer; vice president, tailored therapeutics; vice president, diabetes research; and senior vice president, clinical and product development.

Dan completed his residency training in pathology and fellowship training in neuropathology at the Hospital of the University of Pennsylvania. He received his M.D. from the Perelman School of Medicine, University of Pennsylvania, in 2001, and his Ph.D. in neuroscience from University of Pennsylvania in 2000. Dan earned a Bachelor of Science in molecular biophysics and biochemistry from Yale University in 1994.

Dan Skovronsky is the chief scientific officer of Eli Lilly and Company and serves as Lilly’s executive vice president of science and technology. Dan is also president of Lilly Research Laboratories and president of Lilly Immunology, as well as has responsibility for global business development.

Dan joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals Inc., where he had been CEO since founding the company in 2004. At Lilly, he has held various leadership roles, including chief medical officer; vice president, tailored therapeutics; vice president, diabetes research; and senior vice president, clinical and product development.

Dan completed his residency training in pathology and fellowship training in neuropathology at the Hospital of the University of Pennsylvania. He received his M.D. from the Perelman School of Medicine, University of Pennsylvania, in 2001, and his Ph.D. in neuroscience from University of Pennsylvania in 2000. Dan earned a Bachelor of Science in molecular biophysics and biochemistry from Yale University in 1994.

Dan Skovronsky is the chief scientific officer of Eli Lilly and Company and serves as Lilly’s executive vice president of science and technology. Dan is also president of Lilly Research Laboratories and president of Lilly Immunology, as well as has responsibility for global business development.

Dan joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals Inc., where he had been CEO since founding the company in 2004. At Lilly, he has held various leadership roles, including chief medical officer; vice president, tailored therapeutics; vice president, diabetes research; and senior vice president, clinical and product development.

Dan completed his residency training in pathology and fellowship training in neuropathology at the Hospital of the University of Pennsylvania. He received his M.D. from the Perelman School of Medicine, University of Pennsylvania, in 2001, and his Ph.D. in neuroscience from University of Pennsylvania in 2000. Dan earned a Bachelor of Science in molecular biophysics and biochemistry from Yale University in 1994.

Dan Skovronsky is the chief scientific officer of Eli Lilly and Company and serves as Lilly’s executive vice president of science and technology. Dan is also president of Lilly Research Laboratories and president of Lilly Immunology, as well as has responsibility for global business development.

Dan joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals Inc., where he had been CEO since founding the company in 2004. At Lilly, he has held various leadership roles, including chief medical officer; vice president, tailored therapeutics; vice president, diabetes research; and senior vice president, clinical and product development.

Dan completed his residency training in pathology and fellowship training in neuropathology at the Hospital of the University of Pennsylvania. He received his M.D. from the Perelman School of Medicine, University of Pennsylvania, in 2001, and his Ph.D. in neuroscience from University of Pennsylvania in 2000. Dan earned a Bachelor of Science in molecular biophysics and biochemistry from Yale University in 1994.

In addition to his position at Ovid, Dr. Levin is concurrently the chairman of Ceryvyn Therapeutics Ltd. Before founding Ovid, he was President and CEO of Teva Pharmaceutical Industries. At Bristol-Myers Squibb, as a member of the executive committee, he was the architect of the String of Pearls strategy, which transformed the company and helped set the immuno-oncology revolution in motion. He joined Bristol from Novartis, where he led global strategic alliances. He has served on the boards of Biocon and Lundbeck, and is a past chairman of BIO. He was selected by Endpoints in 2021 as one of the 60 living pioneers of the industry and the recipient of the Albert Einstein Award for Leadership in Life Sciences and the B’nai B’rith Award for Distinguished Achievement. He edited the 2020 bestseller Biotechnology in the Time of Covid-19 and published Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust in May 2026. He holds a doctorate in chromatin structure from Oxford and medical and surgical degrees from Cambridge, and has practiced medicine in England, South Africa, and Switzerland. He received the Albert Einstein Award for Leadership in Life Sciences.

Julie Fleshman has been a global catalyst for change in the fight against pancreatic cancer since losing her dad to the disease, just four months after his diagnosis at the age of 52 at a time when very little was known about the disease, only a handful of researchers were studying it, and the five-year survival rate was just 4%. In 1999, Fleshman was hired as PanCAN’s first employee, became its first Executive Director in 2000 and in 2004, became President and CEO. Under her leadership, PanCAN has grown from a staff of one with annual revenues of $228,000 to an employee team of over 130, raising more than $37 million annually.
During her tenure, advocacy and grassroots efforts have expanded to nearly 60 affiliates nationwide and yielded a 1185% increase in federal funding for pancreatic cancer research, and the organization has invested over $249M in research to date. Fleshman encourages collaboration and convening leading experts and key stakeholders to build a continually expanding community across the country who are focused on accelerating progress for patients.

Margaret (Peggy) Hamburg is an internationally recognized leader in public health and medicine. She is co-president of the InterAcademy Partnership, a consortium of over 150 academies of science, medicine, and engineering from around the world. She recently served as vice-chair of the President's Intelligence Advisory Board and on the Foreign Affairs Advisory Board to the Secretary of State. Prior to this, she was Foreign Secretary for the U.S. National Academy of Medicine and President/Chair of the American Association for the Advancement of Science (AAAS). She previously served as Commissioner of the U.S. FDA and founding Vice President/Senior Scientist at the Nuclear Threat Initiative. Other positions include assistant secretary for planning and evaluation at the U.S. Department of Health and Human Services, NYC Health Commissioner, and Assistant Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. Dr. Hamburg is an elected member of the Council on Foreign Relations, the National Academy of Medicine, the American Academy of Arts and Sciences, and the UK Academy of Medical Sciences. She sits on numerous boards and is the recipient of multiple honorary degrees and awards. She graduated from Harvard College and Medical School, and completed her medical residency at Weill Cornell Medical Center. 

Vardit Ravitsky is President and CEO of the Hastings Center, an independent, nonpartisan bioethics research institute that is among the most prestigious bioethics and health policy institutes in the world. She is a Senior Lecturer on Global Health and Social Medicine at Harvard Medical School. Previously, she was a Full Professor in the School of Public Health at the University of Montreal. She is Past-President of the International Association of Bioethics, and a Fellow of the Canadian Academy of Health Sciences. Her research focuses on the ethics of genomics and reproduction, as well as the ethics and governance of health AI. She is particularly interested in the various ways in which cultural frameworks shape public debate and policy around bioethical issues. She has published over 250 articles and commentaries on bioethical issues and has given over 300 talks world-wide and over 400 media interviews. Ravitsky holds a BA from the Sorbonne University in Paris, an MA from the University of New Mexico in the U.S., and a PhD from Bar-Ilan University in Israel. She has also been a Fellow at the Department of Bioethics at the NIH and faculty in the School of Medicine at the University of Pennsylvania.

Dr. Katherine High is CEO of RhyGaze, Inc., a biotech company focused on restoring vision
in retinal diseases using gene therapy. A physician-scientist, she was a long-time faculty
member at the Perelman School of Medicine at the University of Pennsylvania and an
Investigator at the Howard Hughes Medical Institute at CHOP. Dr. High co-founded Spark
Therapeutics, where she led development of Luxturna, the first FDA-approved gene therapy
for a genetic disease, and of Beqvez, a gene therapy for hemophilia B. She is an elected
member of the National Academy of Sciences, serves on the board of directors of CRISPR
Therapeutics and Incyte, and advises GV (Google Ventures).

As Senior Vice President and Virology Therapeutic Area Head at Gilead Sciences, Jared provides strategic oversight for Gilead’s HIV, Viral Hepatitis, Respiratory, and Emerging Virus programs. He previously served as Gilead’s Vice President of Clinical Development and HIV Franchise Head. Jared has conducted extensive research for over two decades on HIV and other infectious diseases globally. He led the Partners PrEP Study, which led to the approval of Truvada as the first medication for pre-exposure prophylaxis for HIV prevention in 2012 and a second trial that led to the first global approval of the dapivirine vaginal ring as a topical microbicide for HIV prevention in women. In 2022, he oversaw the team that received the approval of Sunlenca, the first HIV capsid inhibitor and medication for HIV dosed once every six months. Prior to joining Gilead Sciences, Jared served as Director of the University of Washington/Fred Hutch Center for AIDS Research, Co-Principal Investigator of the NIH-funded Microbicides Trials Network, and tenured Professor of Global Health, Medicine and Epidemiology at the University of Washington, where he was Vice Dean for Strategy and Faculty Affairs at the School of Public Health. He is Affiliate Professor of Global Health and Medicine at the University of Washington, a Fellow of the Infectious Diseases Society of America, and an elected member of the American Society for Clinical Investigation. He has published over 500 scientific articles on HIV and holds an MD and PhD in epidemiology from the University of Washington.

Dr. Howard Y. Chang is responsible for leading all aspects of discovery research at Amgen. Prior to joining Amgen, Dr. Chang led a research laboratory at Stanford University focused on deciphering regulatory information in the human genome for disease diagnosis and therapy. A physician-scientist and board-certified dermatologist, he served as Professor of Dermatology, Genetics, and Pathology at Stanford and Investigator of the Howard Hughes Medical Institute. He is the winner of the Albany Prize, Lurie Prize in Biomedical Sciences, and NAS Award in Molecular Biology for discoveries of regulatory RNAs and an elected member of the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences. He is a serial entrepreneur having founded five biotech companies. Dr. Chang holds a MD from Harvard Medical School, a PhD in Biology from MIT, and an AB in Biochemical Sciences from Harvard University.

J. Larry Jameson is President of the University of Pennsylvania. He previously led Penn Medicine for more than a decade as Executive Vice President of the University of Pennsylvania for the Health System and Dean of the Raymond and Ruth Perelman School of Medicine.
While leading Penn Medicine, he oversaw the opening of the largest capital project in the University’s history and the creation of the Serving a Changing World strategic plan. His leadership helped accelerate breakthroughs in CAR T cell therapy, gene-based treatments, and mRNA technology, while fostering a culture of excellence in patient care, research, and education. Before joining Penn in 2011, he was Dean of Northwestern University’s Feinberg School of Medicine and Vice President for Medical Affairs. Earlier, he was Associate Professor of Medicine and Chief of the Thyroid Unit at Massachusetts General Hospital. A leading physician-scientist, Dr. Jameson has made seminal contributions to understanding the genetic basis of hormonal disorders. He has authored more than 350 scientific publications, co-edited Harrison’s Principles of Internal Medicine, and held leadership roles in major medical and scientific organizations. His honors include election to the National Academy of Medicine and the American Academy of Arts and Sciences, as well as awards from the Endocrine Society, American Thyroid Association, and American College of Surgeons.

Dr. Renee Wegrzyn, PhD, is the Co-Founder of Transfyr, a physical AI company focused on
leveraging scientific observability to reduce “science friction” and make biological research more
interpretable, robust, and transferable. Most recently, she served as inaugural Director of the Advanced Research Projects Agency for Health (ARPA-H) from 2022 to 2025, where she built the agency from zero-to-one and managed a $4 billion portfolio to accelerate transformative health innovation. A veteran of the ARPA model, Renee previously led breakthrough portfolios in gene editing and biomanufacturing at DARPA and served as a technical advisor to IARPA. Her private sector experience includes leadership roles at Ginkgo Bioworks as VP of Business Development and Head of Innovation, several diagnostic start-ups, and serves on multiple company and advisory boards. Recognized as a TIME 100 Innovator, Rock Health Top 50 Digital Health Innovator, and recipient of the Superior Public Service Medal, Renee holds a BS and PhD in Applied Biology and Bioengineering from Georgia Tech.

Dr. Michael Rosenblatt’s career has been in academia, pharma and biotech/venture. He is a physician-scientist, now advising biotech and pharma companies, as well as serving on boards. He serves on the Harvard University Board of Overseers.

Currently he is an advisory partner at Ascenta Capital and senior advisor to Bain Capital Life Sciences and Flagship Pioneering. He is also Co-Chair of the Galien Forum and Chair of the Prix Galien USA Awards Committee. Previously, he was Chief Medical Officer of Flagship Pioneering, a Cambridge, MA-based firm that creates innovative biotech companies (Moderna is an example). Before that, he was Merck’s Chief Medical Officer. He also served as Dean of Tufts University School of Medicine, and prior to that, Robert Ebert Professor of Molecular Medicine and George R. Minot Professor at Harvard Medical School. He was President of Beth Israel Deaconess Medical Center and Director of the Harvard-MIT Division of Health Sciences and Technology.

He graduated summa cum laude from Columbia and received his M.D. magna cum laude from Harvard. Internship, residency, and endocrinology training were all at the Massachusetts General Hospital.

Pratap was elected CEO of ZS in July 2021. Prior to this, he led the firm’s global pharmaceuticals practice for nine years, as well as a practice focused on the dynamics of healthcare ecosystems. He founded and led its advanced data science capability track, which focuses on AI. He has also served on ZS’s board of directors since 2012.

Pratap has advised numerous leading companies in the pharmaceutical and healthcare industries on a wide range of issues, including market access and managed care, using AI across the pharmaceutical value chain, marketing mix, sales force strategy and incentive compensation. More recently, his work has focused on developing effective strategies and analytics for changing customers in the new healthcare ecosystem.

A recognized healthcare industry expert, Pratap regularly contributes his insights to publications including The Wall Street Journal, Bloomberg Businessweek, Business Insider, Fortune, Medical Marketing & Media, NPR, Pharmaceutical Executive and others. His thought leadership work focuses on topics as diverse as healthcare policy; life sciences companies’ new commercial and organizational models; and the evolving relationships between patients, providers and payers and the life sciences organizations that serve them.

Pratap holds a Ph.D. in artificial intelligence from the University of California, Berkeley and a B.Tech from the Indian Institute of Technology Delhi. He also serves as a Trustee of the Virtua Health System in New Jersey and chairs its Innovation committee.

Rob Davis is chairman of the board and chief executive officer of Merck. Previously, Rob served as Merck’s president, responsible for the company’s operating divisions — Human Health, Animal Health, Manufacturing and Merck Research Laboratories. Prior to that, he was executive vice president, Global Services, and the company’s chief financial officer.

Rob joined the company as chief financial officer in 2014 with additional responsibility for real estate operations, corporate strategy and business development. In 2016, his role was expanded to include responsibility for information technology and procurement, forming Global Services. He became president in April 2021, CEO and a member of the board of directors on July 1, 2021, and chairman of the board on December 1, 2022.

Prior to joining Merck, Rob was corporate vice president and president of Baxter’s medical products business. During his tenure at Baxter, he held several other positions, including president of Baxter’s renal business, chief financial officer and treasurer. Before joining Baxter in 2004, Rob held numerous positions of increasing responsibility over 14 years at Eli Lilly and Company.

Rob serves on the board of directors for Duke Energy Corporation, one of America’s largest energy holding companies, and is chair of its finance and risk management committee and a member of the corporate governance committee. In addition, Rob is a member of the Northwestern Law Board at the Northwestern University Pritzker School of Law. He is also a board member of Project HOPE, a nonprofit organization focused on empowering health care workers to deliver expert care when and where it is needed most, and of Catalyst, a global nonprofit that promotes equal access to career opportunities and corporate leadership for women.

Rob received his J.D. from the Northwestern University Pritzker School of Law, his M.B.A. from Northwestern University’s Kellogg Graduate School of Management and his bachelor’s degree in finance from Miami University.

Joaquin Duato is Chairman and Chief Executive Officer of Johnson & Johnson, the world’s most comprehensive healthcare company, with a unique business model that spans both Innovative Medicine and MedTech. Joaquin became CEO in January 2022 and Chairman in January 2023. Building on 140 years of healthcare innovation, Joaquin has sharpened Johnson & Johnson’s focus to six areas of high-growth and high-unmet medical need: Oncology, Immunology,  euroscience, Cardiovascular, Surgery and Vision. The depth and scale of Johnson & Johnson’s portfolio and pipeline is shaping the future of healthcare. A dual citizen of the U.S. and Spain, Joaquin earned a Master of Business Administration from ESADE in Barcelona, Spain, and a Master of International Management from Thunderbird School of Global Management in Arizona.

Olivier Laureau is President and CEO of the Servier Group and the Servier International Foundation for Research. A graduate of the Panthéon-Assas University in Paris, France, Olivier Laureau joined the Servier Group in 1982 in the Intellectual Property Department before joining the Legal Department where he oversaw international contracts. In 2000, he joined the Finance Department and was appointed Chief Financial Officer of the Group in 2008. As President and CEO of the Group since 2014, Olivier Laureau has undertaken a holistic transformation plan to ensure its independence, development and sustainability and fulfil its vocation: committed to therapeutic progress to serve patient needs. The cornerstones of this strategy are to maximize the potential of the Group's medicines in cardiology, metabolism and venous diseases, to research and develop innovative and targeted therapies in the field of oncology, neuroscience and immuno-inflammation, and to drive the drug portfolio development, through a dynamic ecosystem policy, and a strong international expansion. Deeply involved in the debates surrounding the healthcare sector at French and international levels, Olivier Laureau is a member of the Board of Directors of the G5, an organization of leading French pharmaceutical companies. He is also a Board Member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and a member of the Biopharmaceutical CEOs Roundtable (BCR), a global policy forum gathering CEOs of the member-companies of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).

Mr Paulsen joined the Ferring Board of Directors in July 2021, and became Chairman of the Board in 2023. Since 2020, he has also served as Chairman of Ferring Ventures SA.

He is a member of the Harvard Medical School Board of Fellows and Chairman of the Audit and Finance Committee of the State Pension Fund of Georgia. Additionally, he is Chairman of the International School of Economics at Tbilisi State University, having previously served as Senior Advisor to the Vice Prime Minister of Georgia.

Before joining Ferring, Mr Paulsen worked at Mars Inc., Coca-Cola, and Credit Suisse. He holds a Master’s degree in Finance from the London School of Economics and Political Science and is a Fellow of the Chartered Institute of Management Accountants in the UK.

Mr Paulsen joined the Ferring Board of Directors in July 2021, and became Chairman of the Board in 2023. Since 2020, he has also served as Chairman of Ferring Ventures SA.

He is a member of the Harvard Medical School Board of Fellows and Chairman of the Audit and Finance Committee of the State Pension Fund of Georgia. Additionally, he is Chairman of the International School of Economics at Tbilisi State University, having previously served as Senior Advisor to the Vice Prime Minister of Georgia.

Before joining Ferring, Mr Paulsen worked at Mars Inc., Coca-Cola, and Credit Suisse. He holds a Master’s degree in Finance from the London School of Economics and Political Science and is a Fellow of the Chartered Institute of Management Accountants in the UK.